Skystar to File Financial Results for Third Quarter of Fiscal 2013 on Thursday, November 14, 2013 Conference Call to follow Friday, November 15, 2013 at 7:45 AM (ET) XI'AN, CHINA -- (Marketwired) -- 11/14/13 -- Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"), a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, will file its financial results for the third quarter of fiscal 2013 on Thursday November 14, 2013 by close of the business day. Conference Call Information The Company will host a conference call the next morning Friday, November 15, 2013 to discuss its third quarter financial results. Skystar's conference call will begin promptly at 7:45 a.m. ET. Mr. Weibing Lu, Skystar's Chairman and Chief Executive Officer, will host the call, which will be webcast live. Webcast The webcast will be made available at: http://www.investorcalendar.com/IC/CEPage.asp?ID=171912. Phone dial-in Telephone access to the conference call will be available in North America by dialing +1 (877) 407-8031 or internationally by dialing +1 (201) 689-8031. An audio replay of the conference call will be available approximately two hours following the conclusion of the call and for the following 30 day period. To access the replay in North America, dial +1 (877) 660-6853 or, when calling internationally, dial +1 (201) 612-7415, referencing conference ID # 13572867. Alternatively you can listen to the replay online at http://www.investorcalendar.com. To be added to the Company's email distribution for future news releases, please send your request to firstname.lastname@example.org. About Skystar Bio-Pharmaceutical Company Skystar is a China-based developer and distributor of veterinary healthcare and medical care products. Skystar has four product lines (veterinary medicines, micro-organisms, vaccines and feed additives) and over 284 products. Skystar has formed strategic sales distribution networks covering 29 provinces throughout China. For additional information, please visit http://www.skystarbio-pharmaceutical.com. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Safe Harbor Statement under the Private Securities Litigatio n Reform Act of 1995: Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time. Contacts: Skystar Bio-Pharmaceutical Company Scott Cramer Director and U.S. Representative (407) 645-4433 Grayling Investor Relations Christopher Chu (646) 284-9426 email@example.com
Skystar to File Financial Results for Third Quarter of Fiscal 2013 on Thursday, November 14, 2013
Press spacebar to pause and continue. Press esc to stop.